S&P 500’s February Winners & Losers, $SHC Investment Case, $BHVN Insider Buy, $GRRR’s $1.8B Deal, and More
Welcome back to the BBAE Blog, your trusted source for the latest investment insights and analyses from the BBAE team. This week, we’re excited to share some highlights that will keep you informed and ahead of the market. Don’t forget, some of our most valuable insights are available exclusively in the BBAE Pro app—download it now to unlock full access!
- S&P 500: The Winners and Losers of February 2025
- McIntyre Partnerships: Sotera Health ($SHC) Investment Case
- Biohaven ($BHVN) Director Doubles Down After Disappointing Earnings
- Trending Tickers: $GRRR’s $1.8B Deal, $GEV-AWS Collaboration, and $ALGM Rejects $6.9B Buyout
Need a reminder of why BBAE? We have one goal: to provide you with exclusive content and data to help you make informed investing decisions. Explore a wealth of market insights and potential investing opportunities that you can’t find anywhere else.
S&P 500: The Winners and Losers of February 2025
February was a rough month for the S&P 500, with the index sliding 1.4% after a strong January. More than half of the 255 companies in the index ended in the red, but a few stocks stood out with impressive gains. Super Micro Computer ($SMCI) soared 45.37% after resolving financial reporting concerns and unveiling strong AI-driven growth projections. Intel ($INTC) climbed 22.13% amid speculation of a potential TSMC partnership and policy support for domestic chip production. Yum! Brands ($YUM) rose 19.82%, boosted by solid earnings and the launch of an AI-driven SaaS tool. On the downside, FMC Corp ($FMC) plunged 33.85% following disappointing earnings, while West Pharmaceutical ($WST) and Celanese ($CE) tumbled over 28% each due to weak guidance and market headwinds. Click here to read the full article.
McIntyre Partnerships: Sotera Health ($SHC) Investment Case
McIntyre Partnerships’ Q4 2024 letter reaffirms their commitment to Sotera Health Company ($SHC) despite the stock’s 24% decline contributing to the fund’s underperformance in 2024. The fund highlights SHC as a high-quality business operating in a duopoly market for medical device sterilization, featuring 55% EBITDA margins, 100% customer retention, and historical 10% growth. Currently trading below 10x 2025 EV/EBITDA (versus historical 18x+), McIntyre believes the market has overreacted to litigation headlines from California and temporary customer destocking issues. With litigation risk deemed overestimated based on previous settlements and management signaling gradual volume improvements for 2025, McIntyre expects a “material reweight” as destocking headwinds fade and the company returns to its historical growth trajectory. Read the full article here.
Biohaven ($BHVN) Director Doubles Down After Disappointing Earnings
Biohaven ($BHVN) stock fell 13.8% on March 3, 2025, following weaker-than-expected quarterly earnings. The disappointing results triggered a sharp decline, but the next day, Biohaven director John W. Childs increased his stake, acquiring 32,700 shares at $30.47 per share, totaling $996K.
According to InsiderEdge data, Childs has a strong long-term track record, with a 100% win rate over one-year time frames across 13 tracked transactions. For full transaction details and the director’s track record, click here.
Trending Tickers: $GRRR’s $1.8B Deal, $GEV-AWS Collaboration, and $ALGM Rejects $6.9B Buyout
This week, several stocks attracted attention due to major developments. Here’s a breakdown:
- Gorilla Technology ($GRRR): Gorilla secured a $1.8 billion agreement to modernize Thailand’s energy grid using AI-driven analytics and cybersecurity solutions. The 15-year project is structured around performance-based revenue, with significant financial impact expected from 2026 onward.
- GE Vernova ($GEV): GE Vernova expanded its partnership with AWS to support AI-driven data centers with electrification and renewable energy solutions. The agreement aligns with increasing energy demands from AI and cloud computing but did not lead to significant stock movement.
- Allegro MicroSystems ($ALGM): Allegro rejected a $6.9 billion buyout offer from Onsemi ($ON), which proposed an all-cash deal at a 57% premium. Allegro’s board deemed the offer inadequate, but Onsemi signaled a willingness to continue negotiations.
Read the full Weekly Highlights article here.
This article is for informational purposes only and is neither investment advice nor a solicitation to buy or sell securities. All investment involves inherent risks, including the total loss of principal, and past performance is not a guarantee of future results. Always conduct thorough research or consult with a financial expert before making any investment decisions. BBAE has no position in any investment mentioned.
